
FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

September 5, 2003

TO: Examiner Christian Fronda
Group 1652
(703) 305-1252

RECEIVED
CENTRAL FAX CENTER

SEP 05 2003

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

FAX NO: (703) 872-9307

OF PAGES (incl. cover): 23

OFFICIAL

Re: U.S. Serial No. 09/731,231, filed December 7, 2000
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES
THEREOF"
Atty. Docket No.: CL001007

A Response to Final Office Action and IDS in the above-identified application follows.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Karl GUEGLER et al.

Art Unit: 1652

Serial No.: 09/731,231

Examiner: C. Fronda

Filed: December 7, 2000

Atty. Docket: CL001007

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
ACID MOLECULES ENCODING HUMAN KINASE
PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

Please charge the fee set forth in §1.17(p) to deposit account number 50-0970.

Furthermore, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date: September 5, 2003

By: 

Justin D. Karjala, Reg No. 43,704

Celera Genomics Corporation
45 West Gude Drive, C2-4#21
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084

OFFICIAL

RECEIVED
CENTRAL FAX CENTER

SEP 05 2003